Side by side
Retatrutide vs Tesofensine
Both are discussed for weight loss. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.
| Retatrutide | Tesofensine | |
|---|---|---|
| What it is | An investigational once-weekly triple agonist acting on the GLP-1, GIP and glucagon receptors. Not approved anywhere. | A triple monoamine reuptake inhibitor, not a peptide and not an incretin. It works on the brain's reward and arousal systems, with the side effects that implies. |
| EvidenceHow much human evidence exists, not how well it works. | Early human trials | Early human trials |
| Regulatory statusReviewed 2026-08-12 | Investigational. Not approved for human use in any jurisdiction. Sold only as a research chemical, with no manufacturing standard behind that label. | Not approved in the United States or the European Union. Development for obesity did not proceed to a completed registration programme in either. Sold as a research chemical, and pharmacologically related to sibutramine, which was withdrawn from major markets over cardiovascular risk. |
| Routes | Subcutaneous | Oral |
| Half-life | 144 hours | 220 hours |
| Cheapest per mgVials only, read from vendors' own listings and dated on the price index. | $1.25/mg | $99.99/mg |
| Median per mg | $5.00/mg | $104.99/mg |
| Vendors with a price | 37 | 2 |
| Storage once mixed | Refrigerated at 2–8 °C. Do not freeze. | Not applicable. This is taken orally. |
Compare two other compounds · The full price index
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.